Gloria Paz Contreras Yametti

Dr. Gloria Paz Contreras Yametti

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti
TOTalia H. Ostrow
Talia H. Ostrow
SJSylwia Jasinski
Sylwia Jasinski
ERElizabeth A. Raetz
Elizabeth A. Raetz
WCWilliam L Carroll
William L Carroll
NENikki Evensen
Nikki Evensen
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer and advances in its clinical and laboratory biology have grown exponentially over the last few decades. Treatment outcome has improved steadily with over 90% of patients surviving 5 years from initial diagnosis. This success can be attributed in part to the development of a risk stratification approach to identify those subsets of patients with an outstanding outcome that might qualify for a reduction in therapy associated with fewer short and long term side effects. Likewise, recognition of patients with an inferior prognosis allows for augmentation of therapy, which has been shown to improve outcome. Among the clinical and biological variables known to impact prognosis, the kinetics of the reduction in tumor burden during initial therapy has emerged as the most important prognostic variable. Specifically, various methods have been used to detect minimal residual disease (MRD) with flow cytometric and molecular detection of antigen receptor gene rearrangements being the most common. However, many questions remain as to the optimal timing of these assays, their sensitivity, integration with other variables and role in treatment allocation of various ALL subgroups. Importantly, the emergence of next generation sequencing assays is likely to broaden the use of these assays to track disease evolution. This review will discuss the biological basis for utilizing MRD in risk assessment, the technical approaches and limitations of MRD detection and its emerging applications.

11 January 2024 in British Journal of Haematology
Verified
Journal Article
Open access
BKBinni Kunvarjee
Binni Kunvarjee
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti
ABAmanda G. Blouin
Amanda G. Blouin
GLGrace E. Linder
Grace E. Linder
PBP. Dayand Borge
P. Dayand Borge
MCMaria I. Cancio
Maria I. Cancio

27 July 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti
NENikki Evensen
Nikki Evensen
JSJennifer M. Schloss
Jennifer M. Schloss
CAClemence Aldebert
Clemence Aldebert
EDEmily Duan
Emily Duan
MWMatthew T. Witkowski
Matthew T. Witkowski

1 September 2024
Verified
Book Chapter
Closed access
PDF file
AEAlexander M. El-Ali
Alexander M. El-Ali
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti
GRGabe Robbins
Gabe Robbins
SLShailee Lala
Shailee Lala
JDJ. Christopher Davis
J. Christopher Davis
ADAndrew J. Degnan
Andrew J. Degnan

10 July 2026
Verified
Book Chapter
Closed access
PDF file
JKJessica Krugman
Jessica Krugman
DCDanielle W. Cohen
Danielle W. Cohen
ERElizabeth A. Raetz
Elizabeth A. Raetz
WCWilliam L Carroll
William L Carroll
GYGloria Paz Contreras Yametti
Gloria Paz Contreras Yametti

18 June 2025
Verified
Preprint
Open access
PCPaul Castillo
Paul Castillo
LOLinah Omer
Linah Omer
NGNicholas Gloude
Nicholas Gloude
CMCatherine McGuinn
Catherine McGuinn
TNTaizo Nakano
Taizo Nakano
JJJill De Jong
Jill De Jong
Pediatric moderate aplastic anemia (MAA) lacks defined diagnostic criteria and a clear standard-of-care due to the limited knowledge of its pathophysiology and natural history. The approach to MAA has been historically inconsistent as the proposed survey demonstrates. To understand current diagnostic and management practices for patients with MAA, a survey was conducted among members of the North American Pediatric Aplastic Anemia Consortium (NAPAAC), including 104 providers across 57 institutions. The survey demonstrates broad variability regarding the working definition, diagnostic work-up, and therapeutic management of children with MAA. The diagnostic work-up and treatment options for children with MAA are largely driven by management guidelines for pediatric severe aplastic anemia (SAA). Treatment triggers, type of therapy, and outcomes varied widely among respondents. Curated next generation sequencing panels and whole exome/whole genome sequencing were included by only 55% and 9% of respondents, respectively which suggests the need to more broadly consider inherited bone marrow failure syndromes in the differential diagnosis for these patients. Effective and risk-adapted treatment for MAA requires a better understanding of the biology, natural history, and treatment outcomes for this heterogeneous population.